VistaGen Therapeutics News

1,44 $ +2,13% +0,03 $
In : 1,2944 € | 16:22:58 Uhr NYSE | Mehr Kurse »
ISIN: US92840H2022
US-Symbol: VTGN
Typ: Aktie

VistaGen Therapeutics News

  
08.10.19 VistaGen Therapeutics Announces Last Patient Completes Dosing in the ELEVATE Phase 2 Clinical Study of AV-101 for Major Depressive Disorder PR Newswire
15.08.19 VistaGen Therapeutics Achieves Target Patient Enrollment in the ELEVATE Study of AV-101 as an Adjunctive Treatment for Major Depressive Disorder ACCESSWIRE
13.08.19 VistaGen Therapeutics Reports Fiscal 2020 First Quarter Financial Results ACCESSWIRE
23.07.19 VistaGen Therapeutics Announces USPTO Grant of Patent for Treatment of Depression with Fast-​Acting PH10 Neuroactive Nasal Spray ACCESSWIRE
25.06.19 VistaGen Therapeutics Reports Fiscal Year 2019 Results and Provides CNS Pipeline Overview ACCESSWIRE
20.06.19 VistaGen Announces Positive Preclinical Data Supporting AV-101's Potential For Treating Levodopa-​Induced Dyskinesia In Patients With Parkinson's Disease, Without The Psychological Side Effects And Safety Concerns Of Amantadine ACCESSWIRE
30.05.19 VistaGen Announces Positive Preclinical Data Supporting AV-101's Potential for Treating Neuropathic Pain Comparable to Pregabalin (Lyrica(R)), without its Side Effects ACCESSWIRE
28.03.19 VistaGen Therapeutics Receives Australian Patent for Treatment of Depression with AV-101 ACCESSWIRE
14.03.19 VistaGen Therapeutics to Present at the Oppenheimer 29th Annual Healthcare Conference on March 19, 2019 ACCESSWIRE
13.03.19 VistaGen Therapeutics Receives Notice of Allowance for Additional U.S. Patent Regarding Methods of Production for AV-101 ACCESSWIRE
07.03.19 VistaGen Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference on March 13, 2019 ACCESSWIRE
06.09.18 SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating VistaGen Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
05.01.17 VistaGen Therapeutics to Present at Biotech Showcase™ 2017 PR Newswire
14.12.16 VistaGen Therapeutics Grants Exclusive Sublicense of Cardiac Stem Cell Technologies to BlueRock Therapeutics PR Newswire
30.11.16 VistaGen Therapeutics to Present at 9th Annual LD Micro Main Event PR Newswire
14.11.16 VistaGen Therapeutics Reports Second Quarter 2017 Financial Results and Business Update PR Newswire
04.10.16 VistaGen Therapeutics Appoints Mark A. McPartland Vice President of Corporate Development and Investor Relations PR Newswire
22.09.16 VistaGen Therapeutics Provides Business Outlook and Sets Corporate Milestones PR Newswire
20.06.16 VistaGen Therapeutics Appoints Pharmaceutical CNS Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer PR Newswire
10.05.16 VistaGen Announces Nasdaq Listing and Pricing of $10.0 Million Public Offering PR Newswire
30.03.16 VistaGen Therapeutics Appoints Jerry Gin, Ph.D., MBA to its Board of Directors PR Newswire
22.03.16 VistaGen Therapeutics Bolsters Clinical and Regulatory Advisory Board with Appointments of Distinguished Key Opinion Leaders in Depression PR Newswire
23.12.15 VistaGen Secures Exclusive Worldwide Commercial Rights to Three Proprietary Stem Cell Technologies from University Health Network PR Newswire
03.11.15 VistaGen Announces First Patient Dosed in NIH-​Sponsored Phase 2A Study of Orally Available AV-101 in Major Depressive Disorder PR Newswire
07.10.15 Dr. Maurizio Fava, Internationally Renowned Expert in the Field of Depression, Joins VistaGen's Clinical and Scientific Advisory Board PR Newswire
16.09.15 Favorable Data on VistaGen Therapeutics' AV-101 for Major Depressive Disorder Published in Peer-​reviewed Journal of Pharmacology and Experimental Therapeutics PR Newswire

Newssuche